Suppr超能文献

轻度卒中的静脉溶栓治疗:美国国立卫生研究院卒中量表(NIHSS)评分3 - 5分与0 - 2分的对比

Intravenous thrombolysis for mild stroke: NIHSS 3-5 Versus NIHSS 0-2.

作者信息

Wang Liyuan, Li Guangshuo, Hao Yahui, Hao Manjun, Xiong Yunyun

机构信息

Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

China National Clinical Research Center for Neurological Diseases, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.

出版信息

J Stroke Cerebrovasc Dis. 2023 May;32(5):107070. doi: 10.1016/j.jstrokecerebrovasdis.2023.107070. Epub 2023 Mar 10.

Abstract

BACKGROUND AND PURPOSE

Studies have shown that mild stroke patients with National Institutes of Health Stroke Scale (NIHSS) score 3-5 but not 0-2 may benefit from the intravenous thrombolysis when compared with antiplatelet therapy. We aimed to compare the safety and effectiveness of thrombolysis in mild stroke with NIHSS score of 0-2 vs. 3-5 and identify the predictors of an excellent functional outcome in a real world longitudinal registry.

METHODS

In a prospective thrombolysis registry, we identified patients with acute ischemic stroke who presented within 4.5 hours of symptom onset and had initial NIHSS scores ≤ 5. Demographic data, medical history, pre-stroke medications, imaging data, and laboratory measures were collected. The outcome of interest was modified Rankin Scale score of 0 to 1 at discharge. Safety outcome was evaluated by syptomatic intracrerebral hemorrhage defined as any decline in neurologic status due to hemorrhage within 36 h. Multivariable regression models were performed to explore the safety and effectiveness in the alteplase-treated patients with admission NIHSS 0-2 vs. 3-5 and identify factors independently associated with an excellent functional outcome.

RESULTS

Of a total of 236 eligible patients, those with an admission NIHSS score of 0-2 (n=80) had a better functional outcome at discharge compared with NIHSS 3-5 group (n=156) (81.3% vs. 48.7%, adjusted odds ratio [aOR] 0.40, 95% confidential interval [CI] 0.17 - 0.94, P=0.04) without increasing the rate of symptomatic intracerebral hemorrhage and mortality. Non-disabling stroke (Model 1: aOR 0.06, 95%CI 0.01-0.50, P=0.01; Model 2: aOR 0.06, 95% CI 0.01-0.48, P=0.01) and prior statin therapy (Model 1: aOR 3.46, 95% CI 1.02-11.70, P=0.046; Model 2: aOR 3.30, 95% CI 0.96-11.30, P=0.06) were independent predictors of excellent outcomes.

CONCLUSIONS

Acute ischemic stroke patients with admission NIHSS 0-2 was associated with better functional outcomes at discharge compared with NIHSS 3-5 within the 4.5-hour time window. Minor stroke severity, non-disabling stroke and prior statin therapy were independent predictors for funcitonal outcomes at discharge. Further studies with large sample size are needed to confirm the findings.

摘要

背景与目的

研究表明,与抗血小板治疗相比,美国国立卫生研究院卒中量表(NIHSS)评分为3 - 5而非0 - 2的轻度卒中患者可能从静脉溶栓治疗中获益。我们旨在比较NIHSS评分为0 - 2与3 - 5的轻度卒中患者溶栓治疗的安全性和有效性,并在一个真实世界的纵向登记研究中确定良好功能结局的预测因素。

方法

在一项前瞻性溶栓登记研究中,我们纳入了症状发作4.5小时内就诊且初始NIHSS评分≤5的急性缺血性卒中患者。收集了人口统计学数据、病史、卒中前用药、影像数据和实验室检查指标。感兴趣的结局是出院时改良Rankin量表评分为0至1。安全性结局通过症状性颅内出血进行评估,定义为36小时内由于出血导致的神经功能状态任何下降。进行多变量回归模型分析,以探讨阿替普酶治疗的入院NIHSS为0 - 2与3 - 5的患者的安全性和有效性,并确定与良好功能结局独立相关的因素。

结果

在总共236例符合条件的患者中,入院NIHSS评分为0 - 2的患者(n = 80)出院时的功能结局优于NIHSS评分为3 - 5的组(n = 156)(81.3%对48.7%,调整优势比[aOR] 0.40,95%置信区间[CI] 0.17 - 0.94,P = 0.04),且未增加症状性颅内出血和死亡率。非致残性卒中(模型1:aOR 0.06,95%CI 0.01 - 0.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验